SHERIDAN, WYOMING – May 7, 2025 – Intuitive (Nasdaq: ISRG), a global leader in minimally invasive care and robotic-assisted surgery, has announced its financial results for the first quarter of 2025, showcasing impressive growth and a strong strategic position in the healthcare technology market. The company's financial performance highlights robust growth in surgical procedures, system placements, and revenue, underscoring its leadership in the evolving field of robotic-assisted surgery.
Robust Growth in da Vinci Procedures and System Placements
In Q1 2025, Intuitive saw a 17% year-over-year increase in worldwide da Vinci procedures, reflecting the growing adoption of its robotic surgery systems. This increase is part of a broader trend towards minimally invasive surgery, where precision, reduced recovery times, and improved patient outcomes are driving demand.
The company placed 367 da Vinci surgical systems in Q1 2025, a notable increase from 313 systems in Q1 2024. Notably, 147 of these placements were for the new da Vinci 5 systems, a significant leap from the 8 systems placed in Q1 2024. This demonstrates continued customer confidence and adoption of Intuitive’s cutting-edge technology.
As of March 31, 2025, the installed base of da Vinci surgical systems reached 10,189 units, up 15% from 8,887 units a year earlier. This growing base positions Intuitive for continued success as healthcare providers increasingly turn to robotic-assisted surgery for a variety of procedures.
Financial Performance Surpasses Expectations
Intuitive's Q1 2025 financial results demonstrated a strong upward trajectory. The company reported revenue of $2.25 billion, marking a 19% increase compared to the same period in 2024. This growth was driven by a higher volume of da Vinci procedures, an increase in system placements, and the expansion of its installed base.
Key revenue highlights for Q1 2025 include:
- Instruments and accessories revenue: Up 18% to $1.37 billion, driven by a 17% increase in da Vinci procedures and a 58% surge in Ion procedures.
- Systems revenue: Increased to $523 million from $418 million in Q1 2024, reflecting strong demand for da Vinci surgical systems, including 147 placements of the new da Vinci 5 model.
GAAP net income for Q1 2025 was $698 million, or $1.92 per diluted share, compared to $545 million, or $1.51 per diluted share, in Q1 2024. Non-GAAP net income, which excludes certain items, was $662 million, or $1.81 per diluted share, up from $541 million, or $1.50 per diluted share, a year earlier.
Strategic Outlook and Future Growth
Looking ahead, Intuitive maintains a positive outlook for the remainder of 2025. The company projects da Vinci procedure growth of 15% to 17% for the year, reflecting continued strong adoption of robotic-assisted surgery across healthcare systems.
Intuitive is also preparing for potential challenges, including the impact of tariffs on its global operations. Despite these factors, the company remains committed to its mission of improving patient outcomes, enhancing the experience for care teams, and reducing the total cost of care. This is in line with Intuitive's broader goal to increase access to minimally invasive procedures.
“We are pleased by the continued customer adoption of our platforms, including the da Vinci 5,” said Gary Guthart, CEO of Intuitive. “As we look ahead, we remain focused on enabling our customers to deliver on their goals: better patient outcomes, improved patient and care team experiences, lower total cost to treat, and increased access to care.”
Conclusion
Intuitive’s Q1 2025 performance highlights its strong market position in robotic-assisted surgery and its continued leadership in the healthcare technology sector. The company’s ongoing investments in innovation, coupled with robust growth in system placements and procedure volumes, set the stage for continued success throughout 2025 and beyond.
For more information, visit Intuitive's website.